Chemical characterization and hypothesis‑generating network pharmacology analysis of Shenfu Qiangxin pill
Eurasian Journal of Medicine and Oncology · 19.11.2026 · 026370506
DOI: 10.36922/ejmo026370506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Medicine and Oncology, online erschienen am 19.11.2026. Verfasst von Haiyun Zhu und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Heart failure represents a heavy global clinical medical burden with unsatisfactory long term outcomes under conventional therapeutic regimens. Traditional Chinese medicine exerts beneficial effects for chronic heart failure management via multi-component and multi-target modes of action. Shenfu Qiangxin pill (SFQXP) is a clinically effective herbal formula for chronic heart failure treatment, yet its systematic chemical profiling and underlying molecular mechanisms remain poorly characterized.
Objective
To characterize the chemical constituents of SFQXP and generate testable hypotheses for heart failure-relevant mechanisms using ultra-high-performance liquid chromatography quadrupole orbitrap high-resolution mass spectrometry (UHPLC-Q-Orbitrap-HRMS), network pharmacology, and molecular docking.
Methods
In vitro extracts and rat medicated serum were analyzed using UHPLC-Q-Orbitrap HRMS. Constituents were tentatively annotated against TCM Pro 2.0 and an in-house compound library. Active compounds were screened via SwissADME. Drug-elated and heart failure-associated targets were retrieved from SwissTargetPrediction, GeneCards, and OMIM. Intersection targets were subjected to protein–protein interaction network construction, core-target filtering, and Gene Ontology/Kyoto Encyclopedia of Genes and Genomes enrichment analyses. AutoDock Vina 1.1.2 was used to evaluate molecular docking between sanggenol A and peroxisome proliferator-activated receptor gamma (PPARG).
Results
A total of 232 non-redundant constituents (186 in vitro, 151 serum-derived; 105 shared) were annotated at MSI Level 2 without authentic reference standards. Thirty-five bioactive candidates and 125 overlapping drug-disease targets were obtained, and 33 core targets were screened. Enrichment analyses highlighted cyclic guanosine monophosphate-protein kinase G, cyclic adenosine monophosphate, and calcium signaling pathways associated with ventricular remodeling. Sanggenol A exhibited favorable in silico predicted binding affinity (−8.3 kcal/mol) to PPARG.
Conclusion
This study profiles SFQXP chemical components and puts forward computational mechanistic hypotheses. Anti-heart failure bioactivity has not been experimentally validated; further cellular and animal‑model experiments are required for verification.
Zitieren
APA
Zhu, H., & Wu, Y. (2026). Chemical characterization and hypothesis‑generating network pharmacology analysis of Shenfu Qiangxin pill. Eurasian Journal of Medicine and Oncology, 0(0), 026370506. https://doi.org/10.36922/ejmo026370506
Vancouver
Zhu H, Wu Y. Chemical characterization and hypothesis‑generating network pharmacology analysis of Shenfu Qiangxin pill. Eurasian Journal of Medicine and Oncology. 2026;0(0):026370506. doi:10.36922/ejmo026370506
BibTeX
@article{Zhu2026,
author = {Zhu, Haiyun and Wu, Yingdong},
title = {Chemical characterization and hypothesis‑generating network pharmacology analysis of Shenfu Qiangxin pill},
journal = {Eurasian Journal of Medicine and Oncology},
year = {2026},
volume = {0},
number = {0},
pages = {026370506},
doi = {10.36922/ejmo026370506}
}
EUVIMED